Expression of CD44 and IDH1 R132H in Gliomas and their Prognostic Relevance

Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G., Carmona, M. A., Prieto-Sanchez, R. M., Barba, I., Martinez-Saez, E., Prudkin, L. et al. (2010). TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell., 18 (6), 655–668.10.1016/j.ccr.2010.10.023Search in Google Scholar

Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., Itinteang, T. (2016). Cancer stem cell hierarchy in glioblastoma multi-forme. Front Surg., 3, 21.Search in Google Scholar

Brown, D. V., Daniel, P. M., D’Abaco, G. M., Gogos, A., Ng, W., Morokoff, A. P., Mantamadiotis, T. (2015). Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme. Oncotarget, 6 (8), 6267–6280.10.18632/oncotarget.3365Search in Google Scholar

Cai, J., Zhu, P., Zhang, C., Li, Q., Wang, Z., Li, G., Wang, G., Yang, P., Li, J., Han, B., Jiang, C., Sun, Y., Jiang, T. (2016). Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget, 7 (13), 16384–16395.10.18632/oncotarget.7650Search in Google Scholar

Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M. R., Kelsey, K. T., Wiencke, J. K. (2011). DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst., 103 (2), 143–153.10.1093/jnci/djq497Search in Google Scholar

Cohen, A., Holmen, S., Colman, H. (2013). IDH1 and IDH2 mutations in gliomas. Curr. Neurol. Neurosci. Rep., 13 (5), 345–345.10.1007/s11910-013-0345-4Search in Google Scholar

Dzwonek, J., Wilczynski, G. M. (2015). CD44: Molecular interactions, signaling and functions in the nervous system. Front Cell Neurosci., 9, 175.10.3389/fncel.2015.00175Search in Google Scholar

Gravendeel, L. A., Kloosterhof, N. K., Bralten, L. B., van Marion, R., Dubbink, H. J., Dinjens, W., Bleeker, F. E., Hoogenraad, C. C., Michiels, E., Kros, J. M., van den Bent, M., Smitt, P. A., French, P. J. (2010). Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum. Mutat., 31 (3), E1186–1199.Search in Google Scholar

Jijiwa, M., Demir, H., Gupta, S., Leung, C., Joshi, K., Orozco, N., Huang, T., Yildiz, V. O., Shibahara, I., de Jesus, J. A., Yong, W. H., Mischel, P. S., Fernandez, S., Kornblum, H. I., Nakano, I. (2011). CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One., 6 (9), e24217.10.1371/journal.pone.0024217Search in Google Scholar

Juratli, T. A., Kirsch, M., Robel, K., Soucek, S., Geiger, K., von Kummer, R., Schackert, G., Krex, D. (2012). IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J. Neurooncol., 108 (3), 403–410.10.1007/s11060-012-0844-1Search in Google Scholar

Kaaijk, P., Pals, S. T., Morsink, F., Bosch, D. A., Troost, D. (1997). Differential expression of CD44 splice variants in the normal human central nervous system. J. Neuroimmunol., 73 (1–2), 70–76.10.1016/S0165-5728(96)00167-1Search in Google Scholar

Klank, R. L., Decker Grunke, S. A., Bangasser, B. L., Forster, C. L., Price, M. A., Odde, T. J., SantaCruz, K. S., Rosenfeld, S. S., Canoll, P., Turley, E. A., McCarthy, J. B., Ohlfest, J. R., Odde, D. J. (2017). Biphasic dependence of glioma survival and cell migration on CD44 expression level. Cell Rep., 18 (1), 23–31.10.1016/j.celrep.2016.12.024549814928052252Search in Google Scholar

Le Mercier, M., Hastir, D., Moles Lopez, X., De Neve, N., Maris, C., Trepant, A. L., Rorive, S., Decaestecker, C., Salmon, I. (2012). A simplified approach for the molecular classification of glioblastomas. PLoS One, 7 (9), e45475.10.1371/journal.pone.0045475Search in Google Scholar

Liu, Y., Han, S. S., Wu, Y., Tuohy, T. M., Xue, H., Cai, J., Back, S. A., Sherman, L. S., Fischer, I., Rao, M. S. (2004). CD44 expression identifies astrocyte-restricted precursor cells. Dev. Biol., 276 (1), 31–46.10.1016/j.ydbio.2004.08.018Search in Google Scholar

Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K. (2016). Astrocytic tumours. In: WHO Classification of Tumours of the Central Nervous System (Fourth Edition). WHO Press, Lyon, pp. 13–53.Search in Google Scholar

Malik, N., Wang, X., Shah, S., Efthymiou, A. G., Yan, B., Heman-Ackah, S., Zhan, M., Rao, M. (2014). Comparison of the gene expression profiles of human fetal cortical astrocytes with pluripotent stem cell derived neural stem cells identifies human astrocyte markers and signaling pathways and transcription factors active in human astrocytes. PLoS One, 9 (5), e96139.10.1371/journal.pone.0096139Search in Google Scholar

Mooney, K. L., Choy, W., Sidhu, S., Pelargos, P., Bui, T. T., Voth, B., Barnette, N., Yang, I. (2016). The role of CD44 in glioblastoma multiforme. J.Clin. Neurosci., 34, 1–5.10.1016/j.jocn.2016.05.012Search in Google Scholar

Motomura, K., Natsume, A., Watanabe, R., Ito, I., Kato, Y., Momota, H., Nishikawa, R., Mishima, K., Nakasu, Y., Abe, T., Namba, H., Nakazato, Y., Tashiro, H., Takeuchi, I., Mori, T., Wakabayashi, T. (2012). Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci., 103 (10), 1871–1879.10.1111/j.1349-7006.2012.02377.xSearch in Google Scholar

Naor, D., Sionov, R. V., Ish-Shalom, D. (1997). CD44: Structure, function, and association with the malignant process. Adv. Cancer Res., 71, 241–319.10.1016/S0065-230X(08)60101-3Search in Google Scholar

Naruse, M., Shibasaki, K., Yokoyama, S., Kurachi, M., Ishizaki, Y. (2013). Dynamic changes of CD44 expression from progenitors to subpopulations of astrocytes and neurons in developing cerebellum. PLoS One., 8 (1), e53109.10.1371/journal.pone.0053109353776923308146Search in Google Scholar

Nobusawa, S., Watanabe, T., Kleihues, P., Ohgaki, H. (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res., 15 (19), 6002–6007.10.1158/1078-0432.CCR-09-071519755387Search in Google Scholar

Ohgaki, H., Kleihues, P. (2013). The definition of primary and secondary glioblastoma. Clin. Cancer Res., 19 (4), 764–772.10.1158/1078-0432.CCR-12-300223209033Search in Google Scholar

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L. et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321 (5897), 1807–1812.Search in Google Scholar

Petrey, A. C., de la Motte, C. A. (2014). Hyaluronan, a crucial regulator of inflammation. Front Immunol., 5, 101.10.3389/fimmu.2014.00101394914924653726Search in Google Scholar

Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., Williams, P. M., Modrusan, Z., Feuerstein, B. G., Aldape, K. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9 (3), 157–173.10.1016/j.ccr.2006.02.01916530701Search in Google Scholar

Pietras, A., Katz, A. M., Ekstrom, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N. M., Huse, J. T., Holland, E. C. (2014). Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell., 14 (3), 357–369.10.1016/j.stem.2014.01.005399904224607407Search in Google Scholar

Popova, S. N., Bergqvist, M., Dimberg, A., Edqvist, P. H., Ekman, S., Hesselager, G., Ponten, F., Smits, A., Sooman, L., Alafuzoff, I. (2014). Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology, 64 (3), 365–379.10.1111/his.12252467047524410805Search in Google Scholar

Prochazka, L., Tesarik, R., Turanek, J. (2014). Regulation of alternative splicing of CD44 in cancer. Cell Signal., 26 (10), 2234–2239.10.1016/j.cellsig.2014.07.01125025570Search in Google Scholar

Ranuncolo, S. M., Ladeda, V., Specterman, S., Varela, M., Lastiri, J., Morandi, A., Matos, E., Bal de Kier Joffe, E., Puricelli, L., Pallotta, M. G. (2002). CD44 expression in human gliomas. J. Surg. Oncol., 79 (1), 30–35.10.1002/jso.1004511754374Search in Google Scholar

Sahlberg, S. H., Spiegelberg, D., Glimelius, B., Stenerlow, B., Nestor, M. (2014). Evaluation of cancer stem cell markers CD133, CD44, CD24: Association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One., 9 (4), e94621.10.1371/journal.pone.0094621399740324760019Search in Google Scholar

Shankar, A., Kumar, S., Iskander, A., Varma, N. R. S., Janic, B., deCarvalho, A., Mikkelsen, T., Frank, J. A., Ali, M. M., Knight, R. A., Brown, S., Arbab, A. S. (2014). Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivo. Chin J. Cancer, 33 (3), 148–158.10.5732/cjc.013.10095396621524016393Search in Google Scholar

Si, D., Yin, F., Peng, J., Zhang, G. (2020). High expression of CD44 predicts a poor prognosis in glioblastomas. Cancer Manag. Res., 12, 769–775.10.2147/CMAR.S233423700685932099472Search in Google Scholar

Sosunov, A. A., Wu, X., Tsankova, N. M., Guilfoyle, E., McKhann, G. M., Goldman, J. E. (2014). Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain. J. Neurosci.,34 (6), 2285–2298.10.1523/JNEUROSCI.4037-13.2014391387224501367Search in Google Scholar

Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P. et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17 (1), 98–110.10.1016/j.ccr.2009.12.020281876920129251Search in Google Scholar

Wang, C., Wang, Z., Chen, C., Fu, X., Wang, J., Fei, X., Yan, X., Xu, R. (2020). A small-molecule CD44 dimerizing inhibitor for glioblastoma treatment. Brit. J. Pharmacol., 11 (19), 491–498.Search in Google Scholar

Ward, P. S., Cross, J. R., Lu, C., Weigert, O., Abel-Wahab, O., Levine, R. L., Weinstock, D. M., Sharp, K. A., Thompson, C. B. (2012). Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogen,31 (19), 2491–2498.10.1038/onc.2011.416327113321996744Search in Google Scholar

Xu, H., Tian, Y., Yuan, X., Wu, H., Liu, Q., Pestell, R. G., Wu, K. (2015). The role of CD44 in epithelial–mesenchymal transition and cancer development. OncoTargets Ther.,8, 3783–3792.Search in Google Scholar

Xu, Y., Stamenkovic, I., Yu, Q. (2010). CD44 attenuates activation of the Hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res., 70 (6), 2455–2464.10.1158/0008-5472.CAN-09-2505284007320197461Search in Google Scholar

Ylagan, L. R., Quinn, B. (1997). CD44 expression in astrocytic tumors. Mod. Pathol., 10 (12), 1239–1246.Search in Google Scholar